Form 144: ELVN insider to sell 4,500 shares via Jefferies on 09/29/2025

Rhea-AI Filing Summary

Enliven Therapeutics (ELVN) filing a Form 144 notifies a proposed brokered sale of 4,500 common shares through Jefferies with an aggregate market value of $90,045, planned for 09/29/2025. The shares were acquired as stock options on 08/09/2022 from the company. The filing shows 59,000,000 shares outstanding for the issuer and discloses prior insider sales of 7,500 shares during the past three months with reported gross proceeds totaling roughly $156,197.50. The filer attests there is no undisclosed material adverse information and the transaction will be executed through a broker.

Positive

• Planned sale routed through a registered broker (Jefferies), indicating standard market execution and oversight
• Acquisition method disclosed: shares to be sold were obtained as stock options on 08/09/2022, not gifts

Negative

• Insider sales recently aggregated: 7,500 shares sold during the past three months, which investors may note
• Proposed sale adds further insider selling (4,500 shares on 09/29/2025), increasing total recent insider dispositions

Insights

Securities Analyst

TL;DR: Routine insider disposition via broker; not clearly material to company valuation based on disclosed sizes.

The Form 144 documents a planned brokered sale of 4,500 shares by an option holder, acquired in 2022, and prior insider sales totaling 7,500 shares in the last three months. Transactions were routed through a major broker, indicating standard market execution. The aggregate values disclosed suggest modest proceeds relative to typical public float sizes; the filing contains the standard attestation regarding undisclosed material information. No earnings, financings, or corporate actions are disclosed here to suggest a broader corporate development.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 mechanics; raises routine governance transparency points but no red flags in the filing itself.

The notice properly identifies the securities as option-originated and provides dates of acquisition and planned sale timing. Repeated recent sales by the same person are disclosed, which governance teams track for insider trading patterns, but the filing includes the required signature attestation about material information. The document does not include any indication of policy breaches or 10b5-1 plan invocation, and no additional governance actions are reported.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	4500	90045.00	59000000	09/29/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock options	Enliven Therapeutics			4500	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	08/27/2025	3250	67038.89
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	07/10/2025	1000	22655.00
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	07/28/2025	3250	66503.61

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Enliven Therapeutics (ELVN) Form 144 disclose about the planned sale?

The Form 144 notifies a brokered sale of 4,500 common shares through Jefferies with an aggregate market value of $90,045, planned for 09/29/2025.

When and how were the shares to be sold by ELVN acquired?

The shares were acquired as stock options on 08/09/2022 from the company; payment details are listed as N/A.

Has the filer sold other Enliven Therapeutics shares recently?

Yes. The filing discloses sales of 7,500 shares in the past three months with combined gross proceeds of approximately $156,197.50.

Does the Form 144 state any undisclosed material information about ELVN?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

How many Enliven Therapeutics shares are outstanding per the filing?

The filing reports 59,000,000 shares outstanding for the issuer.